Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free AKTX Stock Alerts

Akari Therapeutics (AKTX) Competitors

Akari Therapeutics logo
$11.54 +0.07 (+0.64%)
As of 09/4/2026 03:57 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

AKTX vs. OKYO, GANX, CRDF, TELO, and ANVS

Should you buy Akari Therapeutics stock or one of its competitors? Akari Therapeutics's main competitors and comparable companies include OKYO Pharma (OKYO), Gain Therapeutics (GANX), Cardiff Oncology (CRDF), Telomir Pharmaceuticals (TELO), and Annovis Bio (ANVS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Akari Therapeutics compare to OKYO Pharma?

OKYO Pharma (NASDAQ:OKYO) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings.

3.0% of OKYO Pharma shares are held by institutional investors. Comparatively, 5.1% of Akari Therapeutics shares are held by institutional investors. 40.5% of OKYO Pharma shares are held by company insiders. Comparatively, 32.2% of Akari Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, OKYO Pharma's average media sentiment score of 1.89 beat Akari Therapeutics' score of 0.00 indicating that OKYO Pharma is being referred to more favorably in the media.

Company Overall Sentiment
OKYO Pharma Very Positive
Akari Therapeutics Neutral

OKYO Pharma has a beta of 0.03, meaning that its share price is 97% less volatile than the broader market. Comparatively, Akari Therapeutics has a beta of 1.43, meaning that its share price is 43% more volatile than the broader market.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OKYO PharmaN/AN/A-$8.95MN/AN/A
Akari TherapeuticsN/AN/A-$17.30MN/AN/A

OKYO Pharma's return on equity of 0.00% beat Akari Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
OKYO PharmaN/A N/A N/A
Akari Therapeutics N/A -147.45%-74.70%

OKYO Pharma currently has a consensus price target of $5.67, suggesting a potential upside of 260.93%. Akari Therapeutics has a consensus price target of $32.33, suggesting a potential upside of 181.89%. Given OKYO Pharma's higher possible upside, research analysts clearly believe OKYO Pharma is more favorable than Akari Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OKYO Pharma
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Akari Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Summary

OKYO Pharma beats Akari Therapeutics on 6 of the 9 factors compared between the two stocks.

How does Akari Therapeutics compare to Gain Therapeutics?

Akari Therapeutics (NASDAQ:AKTX) and Gain Therapeutics (NASDAQ:GANX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.

Akari Therapeutics' return on equity of -147.45% beat Gain Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Akari TherapeuticsN/A -147.45% -74.70%
Gain Therapeutics N/A -161.59%-118.36%

Akari Therapeutics currently has a consensus target price of $32.33, indicating a potential upside of 181.89%. Gain Therapeutics has a consensus target price of $7.50, indicating a potential upside of 316.67%. Given Gain Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Gain Therapeutics is more favorable than Akari Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Akari Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Gain Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67

5.1% of Akari Therapeutics shares are owned by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are owned by institutional investors. 32.2% of Akari Therapeutics shares are owned by company insiders. Comparatively, 4.2% of Gain Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Akari Therapeutics has higher earnings, but lower revenue than Gain Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Akari TherapeuticsN/AN/A-$17.30MN/AN/A
Gain Therapeutics$50K1,571.04-$20.16M-$0.50N/A

In the previous week, Gain Therapeutics had 8 more articles in the media than Akari Therapeutics. MarketBeat recorded 8 mentions for Gain Therapeutics and 0 mentions for Akari Therapeutics. Gain Therapeutics' average media sentiment score of 0.24 beat Akari Therapeutics' score of 0.00 indicating that Gain Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Akari Therapeutics Neutral
Gain Therapeutics Neutral

Akari Therapeutics has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market. Comparatively, Gain Therapeutics has a beta of 0.2, meaning that its stock price is 80% less volatile than the broader market.

Summary

Gain Therapeutics beats Akari Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Akari Therapeutics compare to Cardiff Oncology?

Akari Therapeutics (NASDAQ:AKTX) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

5.1% of Akari Therapeutics shares are owned by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are owned by institutional investors. 32.2% of Akari Therapeutics shares are owned by company insiders. Comparatively, 8.8% of Cardiff Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Akari Therapeutics currently has a consensus target price of $32.33, indicating a potential upside of 181.89%. Cardiff Oncology has a consensus target price of $7.50, indicating a potential upside of 588.07%. Given Cardiff Oncology's higher possible upside, analysts clearly believe Cardiff Oncology is more favorable than Akari Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Akari Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Cardiff Oncology
1 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.14

Akari Therapeutics has a net margin of 0.00% compared to Cardiff Oncology's net margin of -7,885.43%. Cardiff Oncology's return on equity of -103.10% beat Akari Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Akari TherapeuticsN/A -147.45% -74.70%
Cardiff Oncology -7,885.43%-103.10%-75.52%

Akari Therapeutics has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market. Comparatively, Cardiff Oncology has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market.

In the previous week, Cardiff Oncology had 4 more articles in the media than Akari Therapeutics. MarketBeat recorded 4 mentions for Cardiff Oncology and 0 mentions for Akari Therapeutics. Cardiff Oncology's average media sentiment score of 0.34 beat Akari Therapeutics' score of 0.00 indicating that Cardiff Oncology is being referred to more favorably in the news media.

Company Overall Sentiment
Akari Therapeutics Neutral
Cardiff Oncology Neutral

Akari Therapeutics has higher earnings, but lower revenue than Cardiff Oncology.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Akari TherapeuticsN/AN/A-$17.30MN/AN/A
Cardiff Oncology$590K143.71-$45.85M-$0.60N/A

Summary

Cardiff Oncology beats Akari Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Akari Therapeutics compare to Telomir Pharmaceuticals?

Telomir Pharmaceuticals (NASDAQ:TELO) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

Telomir Pharmaceuticals' return on equity of -102.70% beat Akari Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Telomir PharmaceuticalsN/A -102.70% -90.75%
Akari Therapeutics N/A -147.45%-74.70%

Telomir Pharmaceuticals has a beta of -0.25, suggesting that its stock price is 125% less volatile than the broader market. Comparatively, Akari Therapeutics has a beta of 1.43, suggesting that its stock price is 43% more volatile than the broader market.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Telomir PharmaceuticalsN/AN/A-$10.41M-$0.91N/A
Akari TherapeuticsN/AN/A-$17.30MN/AN/A

5.1% of Akari Therapeutics shares are held by institutional investors. 16.4% of Telomir Pharmaceuticals shares are held by insiders. Comparatively, 32.2% of Akari Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Akari Therapeutics has a consensus price target of $32.33, suggesting a potential upside of 181.89%. Given Akari Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Akari Therapeutics is more favorable than Telomir Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Telomir Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Akari Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

In the previous week, Telomir Pharmaceuticals' average media sentiment score of 0.00 equaled Akari Therapeutics'average media sentiment score.

Company Overall Sentiment
Telomir Pharmaceuticals Neutral
Akari Therapeutics Neutral

Summary

Akari Therapeutics beats Telomir Pharmaceuticals on 7 of the 9 factors compared between the two stocks.

How does Akari Therapeutics compare to Annovis Bio?

Annovis Bio (NYSE:ANVS) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

Annovis Bio has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market. Comparatively, Akari Therapeutics has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market.

In the previous week, Annovis Bio had 2 more articles in the media than Akari Therapeutics. MarketBeat recorded 2 mentions for Annovis Bio and 0 mentions for Akari Therapeutics. Annovis Bio's average media sentiment score of 0.13 beat Akari Therapeutics' score of 0.00 indicating that Annovis Bio is being referred to more favorably in the media.

Company Overall Sentiment
Annovis Bio Neutral
Akari Therapeutics Neutral

15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 5.1% of Akari Therapeutics shares are owned by institutional investors. 20.8% of Annovis Bio shares are owned by company insiders. Comparatively, 32.2% of Akari Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Akari Therapeutics' return on equity of -147.45% beat Annovis Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Annovis BioN/A -685.98% -258.77%
Akari Therapeutics N/A -147.45%-74.70%

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Annovis BioN/AN/A-$28.85M-$1.79N/A
Akari TherapeuticsN/AN/A-$17.30MN/AN/A

Annovis Bio currently has a consensus price target of $12.00, indicating a potential upside of 767.99%. Akari Therapeutics has a consensus price target of $32.33, indicating a potential upside of 181.89%. Given Annovis Bio's higher possible upside, equities analysts clearly believe Annovis Bio is more favorable than Akari Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Annovis Bio
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Akari Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Summary

Akari Therapeutics beats Annovis Bio on 7 of the 11 factors compared between the two stocks.

Get Akari Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AKTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AKTX vs. The Competition

Export
MetricAkari TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$22.33M$3.99B$7.21B$12.89B
Dividend YieldN/A3.60%2.54%9.13%
P/E RatioN/A12.71273.8425.45
Price / SalesN/A1,344.29625.56100.83
Price / CashN/A45.0028.9235.62
Price / Book0.4616.4011.016.39
Net Income-$17.30M-$22.85M$3.49B$358.69M
7 Day Performance9.97%1.43%1.63%0.22%
1 Month Performance63.86%6.00%4.42%-0.10%
1 Year Performance-64.97%49.38%24.21%14.04%

Akari Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AKTX
Akari Therapeutics
2.4344 of 5 stars		$11.47
flat		$32.33
+181.9%		-65.0%$22.33MN/AN/A9
OKYO
OKYO Pharma
3.1674 of 5 stars		$1.51
-0.7%		$5.67
+275.3%		-30.5%$79.77MN/AN/A7
GANX
Gain Therapeutics
2.4304 of 5 stars		$1.77
-1.7%		$7.50
+323.7%		+2.3%$78.56M$50KN/A20
CRDF
Cardiff Oncology
2.5703 of 5 stars		$1.03
+3.7%		$7.50
+628.2%		-49.8%$77.30M$590KN/A20
TELO
Telomir Pharmaceuticals
0.414 of 5 stars		$1.10
-1.8%		N/A-6.5%$77.03MN/AN/A1

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:AKTX) was last updated on 9/7/2026 by MarketBeat.com Staff.
From Our Partners
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel